GEFTICIP is pharmacologically sorted as tyrosine kinase inhibitor which may intrudes on the signal transduction
through EGFR in tumor cells.
GEFTICIP tablets are containing a hostile to tumor specialist known as Gefitinib,
which is synthetically delegated anilinoquinazoline subsidiary.
GEFTICIP tablets are doctor prescribed pharmaceutical which is
utilized by the patients with substantial medicine proposed by therapeutic oncologist
GEFTICIP is principally utilized for treating progressed non small cell lung cancer in quiet whose tumor cells having EGFR exon 19 deletions or exon 21 substitutions.
The reactant development of different tyrosine kinases including the EGFR get controlled by Gefitinib, which may completes up in prevention of tyrosine kinase subordinate tumor advancement
Gefitinib encounters with the uniting of ATP to the tyrosine kinase site of EGRF, through prohibiting receptor autophosphorylation and completing up in confinement of signal transduction.
Gefitinib also connected with the action of cell catch prompting and angiogenesis controlling.
Bioavailability of Gefitinib is 100%
Time to maximium plasma concentration is Gefitinib is 3 to 7 hours after uptake of food.
Gefitinib is bound to human plasma protein by 90%.
Gefitinib metabolism in liver aided by CYP3A4.
Biotransformation of Gefitinib obtained by three pathway;
• Metabolism of N-propoxymorpholino group
• Demethylation of Methoxy substituent on quinazoline
• Oxidative defluorination of halogenated phenyl group
Excretion process of Gefitinib is occurs by hepatic metabolism. Gefitinib eliminated at 86% via feces & 4% via urine.
Half life of Gefitinib is 48 hours & its steady state plasma concentration time is occurs in almost 10 days.
The recommended dose of GEFTICIP is 250mg should be administered orally as single dose by taking with or without food.
If there should be an occurrence of patients neglect to take the GEFTICIP tablets orally, it ought to be dissolve in 4 to 8 ounces of water and blend well.
The blended arrangement ought to be managed orally or through naso gastric tube promptly.
Acute new commencement of or aggravation of pulmonary symptoms
Elevated AST & ALT levels
Worsening of ocular disorders
Skin reactions
Continue the GEFTICIP tablets therapy if toxicity grade changes from severe to grade I.
Interstitial lung disease
Chronic liver impairment
Gastrointestinal perforation
Ulcerative keratitis
In case of this combination, the dose of GEFTICIP should be elevates to 500mg & continue as 250mg after discontinuing the CYP3A4 inducers..
In case of over dosage; Patients should be provided with general supportive managements
Signs & symptoms should be monitored
Postpone or discontinue the GEFTICIP tablets.
Hemodialysis is not effective, because Gefitinib is widely bound to human plasma protein.
The co administration of GEFTICIP tablets with CYP3A4 inducers causes raises the
digestion of Gefitinib and exhausts the Gefitinib plasma fixation.
In this condition, the dosage of GEFTICIP ought to be expanded
to 500mg every day measurement at that point continuing as 250mg subsequent to ending the CYP3A4 inducers.
GEFTICIP joined with drugs influencing the pH causes diminishment in plasma concentration of Gefitinib.
Stay away from the issue by managing GEFTICIP and gastric controllers sooner or later interims.
Proton pump inhibitors: Administer GEFTICIP 12 hours after the last measurements or
12 hours sooner the following dosage of proton pump inhibitor.
H2 receptor opponent: Administer GEFTICIP 6hours after the last dosage or 6 hours sooner
the following measurements of H2 receptor adversary
GEFTICIP with warfarin causes change in prothrombin time and INR esteem, this may finishes up as drain.
Skin issue: GEFTICIP tablet ought to be put off or ended amid serious skin responses.
Developing life fetal harmfulness: GEFTICIP is contraindicated to pregnancy, causes fetal mischief
GI perforation: GEFTICIP tablet ought to be for all time ceased amid this condition.
Diarrhea: In serious loose bowels condition, for all time suspend
Visual scatters: Ocular issue like corneal disintegration, conjunctivitis and dry eye
condition, treatment ought to be ended.
Interstitial lung infection: Interrupt the GEFTICIP tablets and give steady measures.
Liver poisonous quality: Monitor the hepatic capacities and hepatic compounds levels.
GEFTICIP tablets ought to be
withheld or suspend the treatment in serious hepatic impedance condition.
Pregnancy category of Gefitinib is D
GEFTICIP tablets are not used in pregnancy period. Avoid becoming pregnant during therapy.
No breast feeding should be recommended.
The potency & effectivity of Gefitinib should not be evaluated in pediatric patients.
GEFTICIP tablets are contraindicated to pregnancy & lactating women.
Some anaphylactic reactions are produced, if patients are contraindicated to the component of GEFTICIP.
Missed dosage condition ought to be maintained a strategic distance from in the event that missed dosage happen, patients must get exhortation from medicinal oncologist and take after the guidelines.
Then again avoid the missed dosage and take after the normal dosing plan
Stay away from self medicine
Store at 20°C- 25°C
GEFTICIP should use before the medicine expiry date.
Keep away the medicine from sight and reach of the medicine.
GEFTICIP should be disposed in proper way, don’t throw away via waste water or household waste.
million-pharmacy.com is a fully licensed and regulated pharmacy, takes all precautions to strictly abide by
the laws and regulations set forth in the dispensing of prescription medications.
By placing the order for your prescription medicines, you acknowledge and accept
the following terms regarding the purchase of any prescription medicines.
million-pharmacy.com will not dispense any prescription medication without a valid prescription from a licensed physician.
If you are ordering prescription medication(s), you hereby confirm that you will send us a
scanned copy of your valid prescription(s) via email, fax, Whatsapp, or by post, and this prescription shall then be subject to
the scrutiny of and approval by our qualified Pharmacists
The drug information provided in the million-pharmacy.com is for informative purposes only and this Website is not intended to provide
diagnosis, treatment or medical advice. We are not
liable for any adverse effects or harm to you as a result of your reliance on the information in the Website.
million-pharmacy.com requires either the User or Customer or the Caregiver to confirm he/she is completely aware of the
indications, side effects, drug interactions, effects of missed dose or overdose of the medicines he/she orders from us. It is imperative to seek professional advice from your physician before
purchasing or consuming any medicine from million-pharmacy.com
million-pharmacy.com is a Caregiver can order prescription medicines on your behalf.
This information should not be used to decide whether or not to take this Product or any other medicine. Only the healthcare provider has the knowledge and training to decide which medicines are right for a specific patient. This information does not endorse any medicine as safe, effective, or approved for treating any patient or health condition. This is only a brief summary of general information about this Product . It does NOT include all information about the possible uses, directions, warnings, precautions, interactions, adverse effects, or risks that may apply to this product. This information is not specific medical advice and does not replace information you receive from the healthcare provider. You must talk with the healthcare provider for complete information about the risks and benefits of using this product. ,
Portion 'A' First Floor,
Old No. 131, New No. 50,
Pedariyar Koil Street,
Seven Wells,
Chennai - 600001.
Tamilnadu,India.
millionhealthpharmaceuticals@gmail.com
+91-9940472902